CDC42 and adenocarcinoma: To further validate this CDC42-driven transcriptional signature in the context of colorectal cancer, we used RNAseq data for a total of 628 CRC patients from The Cancer Genome Atlas (TCGA) Rectum Adenocarcinoma (READ) and Colon Adenocarcinoma (COAD) datasets [18].